Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alan Symons of AGS Capital in Indianaopolis, Indiana and Allen Silberstein of AGS Capital Group in Miami, Florida are 2 completely different people and 2 completely different funds. The only thing they have in common is their initials.
Alan Symons is the Chairman of AGS Capital http://www.ags-capital.com, a venture capital fund located in Indianopolis, Indiana fund located at 9850 E. 30th Street • Indianapolis, IN 46229 •that invests only in private companies. Mr. Symons was born and raised in Montreal, Canada and now lives on Meridian Street in Indianapolis, Indiana. Mr. Symons started out in the insurance business. This company is registered in Indiana. Both he and the fund are located in Indiana and you can contact him at asymons@ags-capital.com. Mr. Symons is a Member of Meridian Hills Golf and Country Club in Indianapolis, Indiana. He served as the President and Director of the Columbia Club of Indianapolis twice and has been the President of Montreal Curling club, President Lloyds of London NA Names. Alan Symons went to Beaconsfield High School.
Allen Silberstein is the Chief Investment Officer of AGS Capital Group www.agscapitalgroup.com, headquartered in Miami, Florida at 801 Brickell Avenue, Suite 902, Miami Florida 33131 and they invest in public companies. His email address is asilberstein@agscapitalgroup.com. This company was originally registered in New York, then registered in Nevada and filed to do business in Florida. Mr. Silberstein was born and raised in New York and now lives in Miami. Mr. Silberstein went to Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University for Structured Finance. He started his career as a Structured Finance Associate at Cadwalader, Wickersham & Taft and then continued to work at Deutsche Bank and Visium Asset Management before founding AGS Capital Group, LLC.
The only commonality between Alan Symons and Allen Silberstein is they have the same initials “AGS” and that they both invest.
Differences side by side:
Name: Alan G. Symons vs. Allen G. Silberstein
Fund Name: AGS Capital vs. AGS Capital Group
Websites: http://www.ags-capital.com vs. http://www.agscapitalgroup.com/
Linked in profiles: http://www.linkedin.com/profile/view?id=71045624&authType=NAME_SEARCH&authToken=SEbf&locale=en_US&srchid=287654361383507571912&srchindex=3&srchtotal=8&trk=vsrp_people_res_name&trkInfo=VSRPsearchId%3A287654361383507571912%2CVSRPtargetId%3A71045624%2CVSRPcmpt%3Aprimary
Vs.
http://www.linkedin.com/profile/view?id=28765436&goback=.nmp_*1_*1_*1_*1_*1_*1_*1_*1_*1_*1&trk=spm_pic
Fund registration: Indiana vs. Nevada and registered to do business in Florida
Fund Address: 9850 E. 30th Street • Indianapolis, IN 46229 vs. 801 Brickell Avenue, Suite 902, Miami Florida 33131
Born and raised: Montreal, Canada vs. New York, United States
Currently living: Meridian Street Indianapolis, Indiana and Sarasota vs. Miami, Florida
Education: Beaconsfield High School vs. Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University
Email addresses: asymons@ags-capital.com vs. asilberstein@agscapitalgroup.com
Invests in: Private Companies vs. Public Companies
Background: 100th federally incorporated Canadian insurance company vs. Cadwalader, Wickersham & Taft, Deutsche Bank and Visium Asset Management.
Specialties: Acquisitions, buy outs of private companies vs. structured equity and debt investments into public companies.
Differences side by side:
Name: Alan G. Symons vs. Allen G. Silberstein
Fund Name: AGS Capital vs. AGS Capital Group
Websites: http://www.ags-capital.com vs. http://www.agscapitalgroup.com/
Linked in profiles: http://www.linkedin.com/profile/view?id=71045624&authType=NAME_SEARCH&authToken=SEbf&locale=en_US&srchid=287654361383507571912&srchindex=3&srchtotal=8&trk=vsrp_people_res_name&trkInfo=VSRPsearchId%3A287654361383507571912%2CVSRPtargetId%3A71045624%2CVSRPcmpt%3Aprimary
Vs.
http://www.linkedin.com/profile/view?id=28765436&goback=.nmp_*1_*1_*1_*1_*1_*1_*1_*1_*1_*1&trk=spm_pic
Fund registration: Indiana vs. Nevada and registered to do business in Florida
Fund Address: 9850 E. 30th Street • Indianapolis, IN 46229 vs. 801 Brickell Avenue, Suite 902, Miami Florida 33131
Born and raised: Montreal, Canada vs. New York, United States
Currently living: Meridian Street Indianapolis, Indiana and Sarasota vs. Miami, Florida
Education: Beaconsfield High School vs. Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University
Email addresses: asymons@ags-capital.com vs. asilberstein@agscapitalgroup.com
Invests in: Private Companies vs. Public Companies
Background: 100th federally incorporated Canadian insurance company vs. Cadwalader, Wickersham & Taft, Deutsche Bank and Visium Asset Management.
Specialties: Acquisitions, buy outs of private companies vs. structured equity and debt investments into public companies
Alan Symons of AGS Capital in Indianaopolis, Indiana and Allen Silberstein of AGS Capital Group in Miami, Florida are 2 completely different people and 2 completely different funds. The only thing they have in common is their initials.
Alan Symons is the Chairman of AGS Capital http://www.ags-capital.com, a venture capital fund located in Indianopolis, Indiana fund located at 9850 E. 30th Street • Indianapolis, IN 46229 •that invests only in private companies. Mr. Symons was born and raised in Montreal, Canada and now lives on Meridian Street in Indianapolis, Indiana. Mr. Symons started out in the insurance business. This company is registered in Indiana. Both he and the fund are located in Indiana and you can contact him at asymons@ags-capital.com. Mr. Symons is a Member of Meridian Hills Golf and Country Club in Indianapolis, Indiana. He served as the President and Director of the Columbia Club of Indianapolis twice and has been the President of Montreal Curling club, President Lloyds of London NA Names. Alan Symons went to Beaconsfield High School.
Allen Silberstein is the Chief Investment Officer of AGS Capital Group www.agscapitalgroup.com, headquartered in Miami, Florida at 801 Brickell Avenue, Suite 902, Miami Florida 33131 and they invest in public companies. His email address is asilberstein@agscapitalgroup.com. This company was originally registered in New York, then registered in Nevada and filed to do business in Florida. Mr. Silberstein was born and raised in New York and now lives in Miami. Mr. Silberstein went to Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University for Structured Finance. He started his career as a Structured Finance Associate at Cadwalader, Wickersham & Taft and then continued to work at Deutsche Bank and Visium Asset Management before founding AGS Capital Group, LLC.
Alan Symons of AGS Capital in Indianaopolis, Indiana and Allen Silberstein of AGS Capital Group in Miami, Florida are 2 completely different people and 2 completely different funds. The only thing they have in common is their initials.
Alan Symons is the Chairman of AGS Capital http://www.ags-capital.com, a venture capital fund located in Indianopolis, Indiana fund located at 9850 E. 30th Street • Indianapolis, IN 46229 •that invests only in private companies. Mr. Symons was born and raised in Montreal, Canada and now lives on Meridian Street in Indianapolis, Indiana. Mr. Symons started out in the insurance business. This company is registered in Indiana. Both he and the fund are located in Indiana and you can contact him at asymons@ags-capital.com. Mr. Symons is a Member of Meridian Hills Golf and Country Club in Indianapolis, Indiana. He served as the President and Director of the Columbia Club of Indianapolis twice and has been the President of Montreal Curling club, President Lloyds of London NA Names. Alan Symons went to Beaconsfield High School.
Allen Silberstein is the Chief Investment Officer of AGS Capital Group www.agscapitalgroup.com, headquartered in Miami, Florida at 801 Brickell Avenue, Suite 902, Miami Florida 33131 and they invest in public companies. His email address is asilberstein@agscapitalgroup.com. This company was originally registered in New York, then registered in Nevada and filed to do business in Florida. Mr. Silberstein was born and raised in New York and now lives in Miami. Mr. Silberstein went to Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University for Structured Finance. He started his career as a Structured Finance Associate at Cadwalader, Wickersham & Taft and then continued to work at Deutsche Bank and Visium Asset Management before founding AGS Capital Group, LLC.
The only commonality between Alan Symons and Allen Silberstein is they have the same initials “AGS” and that they both invest.
Differences side by side:
Name: Alan G. Symons vs. Allen G. Silberstein
Fund Name: AGS Capital vs. AGS Capital Group
Websites: http://www.ags-capital.com vs. http://www.agscapitalgroup.com/
Linked in profiles: http://www.linkedin.com/profile/view?id=71045624&authType=NAME_SEARCH&authToken=SEbf&locale=en_US&srchid=287654361383507571912&srchindex=3&srchtotal=8&trk=vsrp_people_res_name&trkInfo=VSRPsearchId%3A287654361383507571912%2CVSRPtargetId%3A71045624%2CVSRPcmpt%3Aprimary
Vs.
http://www.linkedin.com/profile/view?id=28765436&goback=.nmp_*1_*1_*1_*1_*1_*1_*1_*1_*1_*1&trk=spm_pic
Fund registration: Indiana vs. Nevada and registered to do business in Florida
Fund Address: 9850 E. 30th Street • Indianapolis, IN 46229 vs. 801 Brickell Avenue, Suite 902, Miami Florida 33131
Born and raised: Montreal, Canada vs. New York, United States
Currently living: Meridian Street Indianapolis, Indiana and Sarasota vs. Miami, Florida
Education: Beaconsfield High School vs. Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University
Email addresses: asymons@ags-capital.com vs. asilberstein@agscapitalgroup.com
Invests in: Private Companies vs. Public Companies
Background: 100th federally incorporated Canadian insurance company vs. Cadwalader, Wickersham & Taft, Deutsche Bank and Visium Asset Management.
Specialties: Acquisitions, buy outs of private companies vs. structured equity and debt investments into public companies.
Differences of AGS Capital and AGS Capital Group side by side:
Name: Alan G. Symons vs. Allen G. Silberstein
Fund Name: AGS Capital vs. AGS Capital Group
Websites: http://www.ags-capital.com vs. http://www.agscapitalgroup.com/
Linked in profiles: http://www.linkedin.com/profile/view?id=71045624&authType=NAME_SEARCH&authToken=SEbf&locale=en_US&srchid=287654361383507571912&srchindex=3&srchtotal=8&trk=vsrp_people_res_name&trkInfo=VSRPsearchId%3A287654361383507571912%2CVSRPtargetId%3A71045624%2CVSRPcmpt%3Aprimary
Vs.
http://www.linkedin.com/profile/view?id=28765436&goback=.nmp_*1_*1_*1_*1_*1_*1_*1_*1_*1_*1&trk=spm_pic
Fund registration: Indiana vs. Nevada and registered to do business in Florida
Fund Address: 9850 E. 30th Street • Indianapolis, IN 46229 vs. 801 Brickell Avenue, Suite 902, Miami Florida 33131
Born and raised: Montreal, Canada vs. New York, United States
Currently living: Meridian Street Indianapolis, Indiana and Sarasota vs. Miami, Florida
Education: Beaconsfield High School vs. Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University
Email addresses: asymons@ags-capital.com vs. asilberstein@agscapitalgroup.com
Invests in: Private Companies vs. Public Companies
Background: 100th federally incorporated Canadian insurance company vs. Cadwalader, Wickersham & Taft, Deutsche Bank and Visium Asset Management.
Specialties: Acquisitions, buy outs of private companies vs. structured equity and debt investments into public companies.
Alan Symons of AGS Capital in Indianaopolis, Indiana and Allen Silberstein of AGS Capital Group in Miami, Florida are 2 completely different people and 2 completely different funds. The only thing they have in common is their initials.
Alan Symons is the Chairman of AGS Capital http://www.ags-capital.com, a venture capital fund located in Indianopolis, Indiana fund located at 9850 E. 30th Street • Indianapolis, IN 46229 •that invests only in private companies. Mr. Symons was born and raised in Montreal, Canada and now lives on Meridian Street in Indianapolis, Indiana. Mr. Symons started out in the insurance business. This company is registered in Indiana. Both he and the fund are located in Indiana and you can contact him at asymons@ags-capital.com. Mr. Symons is a Member of Meridian Hills Golf and Country Club in Indianapolis, Indiana. He served as the President and Director of the Columbia Club of Indianapolis twice and has been the President of Montreal Curling club, President Lloyds of London NA Names. Alan Symons went to Beaconsfield High School.
Allen Silberstein is the Chief Investment Officer of AGS Capital Group www.agscapitalgroup.com, headquartered in Miami, Florida at 801 Brickell Avenue, Suite 902, Miami Florida 33131 and they invest in public companies. His email address is asilberstein@agscapitalgroup.com. This company was originally registered in New York, then registered in Nevada and filed to do business in Florida. Mr. Silberstein was born and raised in New York and now lives in Miami. Mr. Silberstein went to Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University for Structured Finance. He started his career as a Structured Finance Associate at Cadwalader, Wickersham & Taft and then continued to work at Deutsche Bank and Visium Asset Management before founding AGS Capital Group, LLC.
The only commonality between Alan Symons and Allen Silberstein is they have the same initials “AGS” and that they both invest.
Differences side by side:
Name: Alan G. Symons vs. Allen G. Silberstein
Fund Name: AGS Capital vs. AGS Capital Group
Websites: http://www.ags-capital.com vs. http://www.agscapitalgroup.com/
Linked in profiles: http://www.linkedin.com/profile/view?id=71045624&authType=NAME_SEARCH&authToken=SEbf&locale=en_US&srchid=287654361383507571912&srchindex=3&srchtotal=8&trk=vsrp_people_res_name&trkInfo=VSRPsearchId%3A287654361383507571912%2CVSRPtargetId%3A71045624%2CVSRPcmpt%3Aprimary
Vs.
http://www.linkedin.com/profile/view?id=28765436&goback=.nmp_*1_*1_*1_*1_*1_*1_*1_*1_*1_*1&trk=spm_pic
Fund registration: Indiana vs. Nevada and registered to do business in Florida
Fund Address: 9850 E. 30th Street • Indianapolis, IN 46229 vs. 801 Brickell Avenue, Suite 902, Miami Florida 33131
Born and raised: Montreal, Canada vs. New York, United States
Currently living: Meridian Street Indianapolis, Indiana and Sarasota vs. Miami, Florida
Education: Beaconsfield High School vs. Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University
Email addresses: asymons@ags-capital.com vs. asilberstein@agscapitalgroup.com
Invests in: Private Companies vs. Public Companies
Background: 100th federally incorporated Canadian insurance company vs. Cadwalader, Wickersham & Taft, Deutsche Bank and Visium Asset Management.
Specialties: Acquisitions, buy outs of private companies vs. structured equity and debt investments into public companies.
Alan Symons of AGS Capital in Indianaopolis, Indiana and Allen Silberstein of AGS Capital Group in Miami, Florida are 2 completely different people and 2 completely different funds. The only thing they have in common is their initials.
Alan Symons is the Chairman of AGS Capital http://www.ags-capital.com, a venture capital fund located in Indianopolis, Indiana fund located at 9850 E. 30th Street • Indianapolis, IN 46229 •that invests only in private companies. Mr. Symons was born and raised in Montreal, Canada and now lives on Meridian Street in Indianapolis, Indiana. Mr. Symons started out in the insurance business. This company is registered in Indiana. Both he and the fund are located in Indiana and you can contact him at asymons@ags-capital.com. Mr. Symons is a Member of Meridian Hills Golf and Country Club in Indianapolis, Indiana. He served as the President and Director of the Columbia Club of Indianapolis twice and has been the President of Montreal Curling club, President Lloyds of London NA Names. Alan Symons went to Beaconsfield High School.
Allen Silberstein is the Chief Investment Officer of AGS Capital Group www.agscapitalgroup.com, headquartered in Miami, Florida at 801 Brickell Avenue, Suite 902, Miami Florida 33131 and they invest in public companies. His email address is asilberstein@agscapitalgroup.com. This company was originally registered in New York, then registered in Nevada and filed to do business in Florida. Mr. Silberstein was born and raised in New York and now lives in Miami. Mr. Silberstein went to Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University for Structured Finance. He started his career as a Structured Finance Associate at Cadwalader, Wickersham & Taft and then continued to work at Deutsche Bank and Visium Asset Management before founding AGS Capital Group, LLC.
The only commonality between Alan Symons and Allen Silberstein is they have the same initials “AGS” and that they both invest.
Differences side by side:
Name: Alan G. Symons vs. Allen G. Silberstein
Fund Name: AGS Capital vs. AGS Capital Group
Websites: http://www.ags-capital.com vs. http://www.agscapitalgroup.com/
Linked in profiles: http://www.linkedin.com/profile/view?id=71045624&authType=NAME_SEARCH&authToken=SEbf&locale=en_US&srchid=287654361383507571912&srchindex=3&srchtotal=8&trk=vsrp_people_res_name&trkInfo=VSRPsearchId%3A287654361383507571912%2CVSRPtargetId%3A71045624%2CVSRPcmpt%3Aprimary
Vs.
http://www.linkedin.com/profile/view?id=28765436&goback=.nmp_*1_*1_*1_*1_*1_*1_*1_*1_*1_*1&trk=spm_pic
Fund registration: Indiana vs. Nevada and registered to do business in Florida
Fund Address: 9850 E. 30th Street • Indianapolis, IN 46229 vs. 801 Brickell Avenue, Suite 902, Miami Florida 33131
Born and raised: Montreal, Canada vs. New York, United States
Currently living: Meridian Street Indianapolis, Indiana and Sarasota vs. Miami, Florida
Education: Beaconsfield High School vs. Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University
Email addresses: asymons@ags-capital.com vs. asilberstein@agscapitalgroup.com
Invests in: Private Companies vs. Public Companies
Background: 100th federally incorporated Canadian insurance company vs. Cadwalader, Wickersham & Taft, Deutsche Bank and Visium Asset Management.
Specialties: Acquisitions, buy outs of private companies vs. structured equity and debt investments into public companies.
Alan Symons of AGS Capital in Indianaopolis, Indiana and Allen Silberstein of AGS Capital Group in Miami, Florida are 2 completely different people and 2 completely different funds. The only thing they have in common is their initials.
Alan Symons is the Chairman of AGS Capital http://www.ags-capital.com, a venture capital fund located in Indianopolis, Indiana fund located at 9850 E. 30th Street • Indianapolis, IN 46229 •that invests only in private companies. Mr. Symons was born and raised in Montreal, Canada and now lives on Meridian Street in Indianapolis, Indiana. Mr. Symons started out in the insurance business. This company is registered in Indiana. Both he and the fund are located in Indiana and you can contact him at asymons@ags-capital.com. Mr. Symons is a Member of Meridian Hills Golf and Country Club in Indianapolis, Indiana. He served as the President and Director of the Columbia Club of Indianapolis twice and has been the President of Montreal Curling club, President Lloyds of London NA Names. Alan Symons went to Beaconsfield High School.
Allen Silberstein is the Chief Investment Officer of AGS Capital Group www.agscapitalgroup.com, headquartered in Miami, Florida at 801 Brickell Avenue, Suite 902, Miami Florida 33131 and they invest in public companies. His email address is asilberstein@agscapitalgroup.com. This company was originally registered in New York, then registered in Nevada and filed to do business in Florida. Mr. Silberstein was born and raised in New York and now lives in Miami. Mr. Silberstein went to Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University for Structured Finance. He started his career as a Structured Finance Associate at Cadwalader, Wickersham & Taft and then continued to work at Deutsche Bank and Visium Asset Management before founding AGS Capital Group, LLC.
The only commonality between Alan Symons and Allen Silberstein is they have the same initials “AGS” and that they both invest.
Differences side by side:
Name: Alan G. Symons vs. Allen G. Silberstein
Fund Name: AGS Capital vs. AGS Capital Group
Websites: http://www.ags-capital.com vs. http://www.agscapitalgroup.com/
Linked in profiles: http://www.linkedin.com/profile/view?id=71045624&authType=NAME_SEARCH&authToken=SEbf&locale=en_US&srchid=287654361383507571912&srchindex=3&srchtotal=8&trk=vsrp_people_res_name&trkInfo=VSRPsearchId%3A287654361383507571912%2CVSRPtargetId%3A71045624%2CVSRPcmpt%3Aprimary
Vs.
http://www.linkedin.com/profile/view?id=28765436&goback=.nmp_*1_*1_*1_*1_*1_*1_*1_*1_*1_*1&trk=spm_pic
Fund registration: Indiana vs. Nevada and registered to do business in Florida
Fund Address: 9850 E. 30th Street • Indianapolis, IN 46229 vs. 801 Brickell Avenue, Suite 902, Miami Florida 33131
Born and raised: Montreal, Canada vs. New York, United States
Currently living: Meridian Street Indianapolis, Indiana and Sarasota vs. Miami, Florida
Education: Beaconsfield High School vs. Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University
Email addresses: asymons@ags-capital.com vs. asilberstein@agscapitalgroup.com
Invests in: Private Companies vs. Public Companies
Background: 100th federally incorporated Canadian insurance company vs. Cadwalader, Wickersham & Taft, Deutsche Bank and Visium Asset Management.
Specialties: Acquisitions, buy outs of private companies vs. structured equity and debt investments into public companies.
Alan Symons of AGS Capital in Indianaopolis, Indiana and Allen Silberstein of AGS Capital Group in Miami, Florida are 2 completely different people and 2 completely different funds. The only thing they have in common is their initials.
Alan Symons is the Chairman of AGS Capital http://www.ags-capital.com, a venture capital fund located in Indianopolis, Indiana fund located at 9850 E. 30th Street • Indianapolis, IN 46229 •that invests only in private companies. Mr. Symons was born and raised in Montreal, Canada and now lives on Meridian Street in Indianapolis, Indiana. Mr. Symons started out in the insurance business. This company is registered in Indiana. Both he and the fund are located in Indiana and you can contact him at asymons@ags-capital.com. Mr. Symons is a Member of Meridian Hills Golf and Country Club in Indianapolis, Indiana. He served as the President and Director of the Columbia Club of Indianapolis twice and has been the President of Montreal Curling club, President Lloyds of London NA Names. Alan Symons went to Beaconsfield High School.
Allen Silberstein is the Chief Investment Officer of AGS Capital Group www.agscapitalgroup.com, headquartered in Miami, Florida at 801 Brickell Avenue, Suite 902, Miami Florida 33131 and they invest in public companies. His email address is asilberstein@agscapitalgroup.com. This company was originally registered in New York, then registered in Nevada and filed to do business in Florida. Mr. Silberstein was born and raised in New York and now lives in Miami. Mr. Silberstein went to Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University for Structured Finance. He started his career as a Structured Finance Associate at Cadwalader, Wickersham & Taft and then continued to work at Deutsche Bank and Visium Asset Management before founding AGS Capital Group, LLC.
The only commonality between Alan Symons and Allen Silberstein is they have the same initials “AGS”
Differences side by side:
Name: Alan G. Symons vs. Allen G. Silberstein
Fund Name: AGS Capital vs. AGS Capital Group
Linked in profiles: http://www.linkedin.com/profile/view?id=71045624&authType=NAME_SEARCH&authToken=SEbf&locale=en_US&srchid=287654361383507571912&srchindex=3&srchtotal=8&trk=vsrp_people_res_name&trkInfo=VSRPsearchId%3A287654361383507571912%2CVSRPtargetId%3A71045624%2CVSRPcmpt%3Aprimary
Vs.
http://www.linkedin.com/profile/view?id=28765436&goback=.nmp_*1_*1_*1_*1_*1_*1_*1_*1_*1_*1&trk=spm_pic
Fund registration: Indiana vs. Nevada and registered to do business in Florida
Fund Address: 9850 E. 30th Street • Indianapolis, IN 46229 vs. 801 Brickell Avenue, Suite 902, Miami Florida 33131
Born and raised: Montreal, Canada vs. New York, United States
Currently living: Meridian Street Indianapolis, Indiana and Sarasota vs. Miami, Florida
Education: Beaconsfield High School vs. Shenendehowa High School, Binghamton University, Boston University Law School, Hofstra Law School and New York University
Email addresses: asymons@ags-capital.com vs. asilberstein@agscapitalgroup.com
Invests in: Private Companies vs. Public Companies
Background: 100th federally incorporated Canadian insurance company vs. Cadwalader, Wickersham & Taft, Deutsche Bank and Visium Asset Management.
Specialties: Acquisitions, buy outs of private companies vs. structured equity and debt investments into public companies.
The only things these two people have in common is their initials “AGS” and that they both invest.
Different between AGS Capital and AGS Capital Group:
Alan Symons of AGS Capital in Indiana and Allen Silberstein of AGS Capital Group in Miami are 2 completely different people and 2 completely different funds that are located in different states and invest differently, the only thing they have in common is their Initials. Alan Symons is the Chairman of AGS Capital, a venture capital fund located in Indiana fund located at 9850 E. 30th Street • Indianapolis, IN 46229 •that invests in private companies. This company is registered in Indiana. Both he and the fund are located in Indiana and you can contact him at asymons@ags-capital.com.
Allen Silberstein on the other hand is the Chief Investment Officer of AGS Capital Group, headquartered in Miami at 801 Brickell Avenue, Suite 902, Miami Florida 33131 and they invest in public companies. His email address is asilberstein@agscapitalgroup.com. This company was originally registered in New York, then registered in Nevada and filed to do business in Florida.
The only commonality between Alan Symons and Allen Silberstein is they have the same initials “AGS”
Updated:
AGS Capital Group, LLC
801 Brickell Avenue, Suite 902
Miami, Florida, 33131
Phone: (305) 789-6641
Email: asilberstein@agscapitalgroup.com
Website: http://www.agscapitalgroup.com
Miami | New York | Hong Kong | India
With the $100mm Reserve Equity Financing that PGI received from AGS Capital Group, it looks like they are well poised for growth.
Inside Wall Street: Tiny NeoStem Offers a Chinese Health Care Play
Not many investors know much about tiny NeoStem (NBS), which collects and stores adult stem cells for future medical use. Its stock hit a 52-week high of $2.72 last year but has since tumbled to $1.64. But it may soon attract attention that could propel it back to its old high, if not higher. That's because NeoStem has become an unlikely China health care play.The company last year acquired 51% of Suzhou Erye Pharmaceuticals in China, which produces a series of penicillin drugs and cephlasporins, which are antibiotics. NeoStem has yet to make a penny, losing $5 million in 2009. But this year, it stands to become profitable, largely because of its majority interest in Suzhou Erye. In 2009. Suzhou Erye reported revenues of more than $60 million and earnings of $11 million. This year, it's projected to post revenues of $84 million and earnings of $14 million.
When investors get wind of NeoStem's new financial profile, the stock is likely to heat up. "As NeoStem reports consolidated sales and earnings, including the revenue and profits of Suzhou Erye, in the first quarter, we believe the stock will dramatically appreciate," says Allen Silberstein, founder and CEO of AGS Capital Group.
Fast-Growing Antibiotic Producer
Sources close to Suzhou Erye and NeoStem figure that when NeoStem consolidates its first-quarter earnings, it'll likely post revenues of $18 million and net income of $1.7 million. For all of 2010, they estimate NeoStem's revenues will total $90 million and earnings of $10 million. The company declined to comment on the sales and earnings projections.
Suzhou Erye is one of the fastest-growing antibiotic producers in China and should be one of the prime beneficiaries of Beijing's health reform program, which aims to spend $124 billion over the next three years to help provide 90% of China's population with basic medical insurance, according to NeoStem CEO Dr. Robin Smith.
NeoStem is developing stem-cell therapies, she says, and pursues anti-aging initiatives. It operates a network of adult stem-cell collection centers in the U.S., which enable people to store their own stem cells for their personal use in times of future medical need.
From Cardiac Repair to Face-Lifts
NeoStem's foothold in China, says Dr. Smith, allows it to take its patented autologous adult stem-cell extraction and storage business, as well as its numerous therapeutic adult stem-cell applications, to that nation's vast market starting this year. NeoStem will establish a laboratory and distribution system in China, she adds, to market its multiple stem-cell therapies.
In addition, NeoStem has acquired worldwide rights to the use of VSEL, or very small embryonic-like stem cells, Dr. Smith says. The VSELs are adult stem cells that are the same as embryonic stems cells but are found in an adult's own body. NeoStem will market the harvesting, storage and use of these cells to enhance wound healing, cardiac repair, orthopedic rejuvenation and cosmetic uses, including face lifts, says Dr. Robin.
Otis Bradley, analyst at ICM Capital Markets, expects NeoStem will earn more than $12 million in 201l, largely because of the revenues and earnings impact from Suzhou Erye. "The VSELs could revolutionize regenerative medicine and place NeoStem as the leading company in the stem-cell industry," says Bradley.
If all goes as planned with NeoStem's adult stem-cell therapies and its bold venture in China, this $1.64 stock could well turn out to be the kind of undiscovered -- and undervalued -- winner that investors hunger for.
INVO Bioscience (formerly BioXcell) is a Massachusetts-based biotech company that provides a fertility treatment method with conception and embryo development taking place inside the woman's body. This is in contrast to traditional in vitro fertilisation where conception takes place in a container in a laboratory.
Management team
Dr. Claude Ranoux, MD, MS, Founder, President, Chief Scientist
Dr. Ranoux, a noted expert in the field of reproductive health, infertility, and embryology, founded the company INVO Bioscience, invented the INVOcell device, and developed the INVO Procedure.
Katie Karloff, CEO
Karloff started at Boston Scientific (BSX) in 1983, just the 80th person hired, and left in 1997 as Director of Operations when the company had over 13,000 employees and a $30 billion market cap. Karloff has over 25 years of experience in medical device manufacturing, clinical operations, regulatory affairs, and quality systems, and has spent 10 years on senior management teams of start-up organizations.
Robert J. Bowdring, CFO
Bowdring has a strong history in senior financial management with over 25 years as CFO, VP Finance, and Controller in both public and private manufacturing and service companies.
[edit] INVOcell Device
INVO Bioscience is a medical device company focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's product, the INVOcell , is a novel medical device intended for use in infertility treatment, which enables egg fertilization and early embryo development to occur inside the patient's vaginal cavity. The INVOcell device has received CE Mark approval and is currently being marketed in Europe, South America and other parts of the world.
Developed by INVO's President and Chief Scientist Dr. Claude Ranoux, more than 800 clinical cases using prototype devices have been published in medical journals, showing INVO was equivalent to IVF in terms of efficacy. Additionally, the company has 5 current patents on the INVOcell device and INVO procedure.
The five INVO patents include: (1) Process for intrauterine fertilization in mammals and device for implantation thereof. U.S. Patent #5084004; Invention ID BIE113394 (2) Spontaneous cycle fertilization. U.S. Patent #5532155; Invention ID BIE114519 (3) Container assembly for intravaginal fertilization and culture, and embryo transfer and method of intravaginal culture employing such a container. U.S. Patent #6050935; Invention ID BIE117061 (4) Incubation and/or storage container system and method. U.S. Patent #10/544990; Invention ID BIE117249 (5) Inspection Block for use in microscopic inspection of embryos or other biological matter insides a container unit. U.S. Patent #12/258874; Invention ID BIF117771.
[edit] INVO Procedure
The INVO procedure is a simple and effective infertility treatment, which uses the INVOcell device, eliminating the need for laboratory equipment required for conventional methods of IVF, thereby reducing the overall cost. During the procedure, eggs are combined with sperm inside the INVOcell device and placed inside the patient's vaginal cavity where it remains for three days. This allows the woman's body to provide a nurturing environment in which conception and early embryo development take place. In late October 2009, INVO Bioscience (OTC: IVOB.OB) announced the results of a clinical trial conducted at the CECOFLES Center for Fertility and Sterility, revealing an ongoing pregnancy rate of 36%. On February 3, 2010, the company confirmed this 36% pregnancy rate, when they followed up with the results of a clinical trial with twice as many patients.
By averaging data from the Jones Institute for Reproductive Medicine, New York Center for Human Reproduction and national statistics from the American Pregnancy Association, IVF carries an average pregnancy rate of approximately 32% and a multiple birth rate of 23.7%.
Additionally, INVO's study showed a multiple pregnancy rate of just 6%, which is a significant decrease from the multiple pregnancy rate of conventional IVF procedures, with an average higher than 20%.
[edit] Infertility Treatment Market
The American Society for Reproductive Medicine (ASRM) considers a marriage barren or infertile when pregnancy has not occurred after a year of intercourse without contraception. For centuries, women around the world have been faced with ostracism, cultural backlash and negative stigmas attached to the inability to conceive and give birth to a child. Infertility places a large strain on women and married couples because it toys with our natural instinct as human beings to procreate and raise a family.
Some may view this as constant, growing problem within the human condition, while others in the field of medicine and biotechnology have taken matters into their own hands. In fact, it's quite interesting that something so primal has just started to turn into a bull market.
According to ASRM's 2004 figures for the infertility treatment market in the United States, infertility drugs made up 46% of the total market, while in vitro fertilization (IVF) came in as a close second, accounting for 36% of the $3 billion market. But, that was several years ago and many things in the medical field have changed. The American Fertility Association (AFA) reports that 1 in 6 (or 17%) of couples are infected by infertility, with more than 7.3 million infertile couples in the United States alone. On a global scale, the European Society of Reproduction and Embryology (ESHRE) estimates there's an estimated 150 million infertile couples of reproductive age.
Why such a large number? The biological and environmental causes of infertility seem to be increasing as time moves on, with several large countries (e.g. Russia) actually reporting decreasing population rates.
Female factors of infertility include endometriosis, ectopic pregnancies, polycystic ovary syndrome (PCOS), pelvic inflammatory disease (PID), damage caused by sexually transmitted infections and diseases, obesity, malnutrition, ovulatory disorders and age.
Many people may be surprised at the massive number of infertile couples in the world, but people often forget that problems with infertility can be associated with male factors as well. In fact, male factors attribute to as much as 40% of infertility cases.
Male factors include, but are not limited to, low sperm count, sperm immobility, exposure to hazardous wastes and substances, testicular trauma or torsion, prescription drugs, history of cancer, hernia repair, obesity, smoking, alcohol use and lack of exercise.
Certainly, these factors come together to represent a market but only a small fraction (.5%) of the estimated 150 million infertile couples will be able to receive infertility treatment and have the chances of being blessed with a child.
INVO Bioscience does not intend to compete directly with conventional IVF procedures. Rather, INVO plans to target the remaining 99.5% of the 150 million infertile couples who would otherwise go untreated. In fact, The National Infertility Association suggests that the main reasons couples do not utilize IVF as an infertility treatment is because of its cost and geographic availability. Various countries around the world have problems with infertility and the statistics are quite striking:
o China has an infertility rate of 15% to 20%, with approximately 10 million infertile couples o India has an infertility rate of 15%, with an estimated 14 million infertile couples o Brazil has an estimated 16 million infertile couples o Russia has a 13% infertility rate, 18 million infertile couples and a decreasing populate rate of 7% o Canada has a 17% infertility rate o Pakistan has the highest infertility rate in the world (29%) and has an estimated 5 million infertile couples o Australia has an infertility rate of 17%
Due to the high cost of infertility treatments, there are a growing number of countries around the world whose governments offer reimbursement and other funding for IVF. Currently, this list includes Australia, Belgium, Denmark, Finland, Netherlands, Sweden, Israel, Austria, Germany, parts of Canada and 15 states in the United States. Some of the main reasons why government funding for infertility treatments is not widespread is because of the ethical and moral issues and overall cost associated with traditional IVF. This includes the creation, storage and disposal of excess and frozen embryos.
Again, the INVO procedure could become a more favorable form of infertility treatment because it does not advocate for the production of excess embryos. Furthermore, the freezing and storage of excess embryos is not an issue with the INVO procedure because the embryos are taken from the INVOcell device and transferred directly to the womb. Additionally, no more than two embryos are transferred during the INVO procedure. Not only does this follow ASRM guidelines of transferring a maximum of two embryos, it also dramatically reduces the chances of multiple births, advocating for the health and safety of mother and unborn child, and an overall lower-cost of care.
[edit] Price Comparison
INVO Bioscience (OTC: IVOB.OB) has positioned its INVO procedure as a more natural and cost effective infertility treatment. In fact, the approximate cost of setting up an INVO center is $30,000, compared to $500,000 for an IVF laboratory, which requires a stable power supply, clean lab maintenance and additional equipment needed to imitate the environmental conditions inside a woman's body. In the United States, most IVF procedures range in price from $12,000 to $15,000 per cycle, with most procedures requiring three cycles. That means IVF can cost as much as $45,000 and that does not include the cost of additional assisted reproductive technologies (ART) associated with IVF, including IUI (intrauterine insemination), sperm donor, egg donor, frozen embryo transfer (FET), intracytoplasmic sperm injection (ISCI) and the storage of embryos. Depending on the specific problems associated with a couple's infertility, these additional technologies may or may not be necessary.
Nevertheless, it's quite interesting to know that the approximate cost of the INVO procedure is $13,888 per pregnancy. Even if we give IVF the benefit of the doubt and a low-end estimated cost of $36,000, the INVO procedure is 60% less expensive.
[edit] Market Penetration
Over the past year, INVO Bioscience has made tremendous progress, penetrating the infertility treatment markets in five continents. Currently, the company has thirteen distribution partners, including CECOFLES Center for Fertility and Sterility, CER Center for Human Reproduction, Galaxy Pharma, Daxley Group, Nacer Infertility Clinic, Gonagen, STAR IVF, Progressive Group, ENVI Med, Meditech, Medek Medikal, and Delfran Pharmaceuticals.
With this network, INVO Bioscience has been able to establish distribution of the patented INVOcell device to 24 countries---Canada, Columbia, Guatemala, Egypt, Argentina, Brazil, Chile, Uruguay, Ecuador, Panama, Mexico, Peru, Turkey, Pakistan, Bulgaria, South Africa, Madagascar, Seychelles, Mauritius, Namibia, Botswana, Mozambique, Kenya and Angola; 5 countries with direct product sales---Togo, Cameroon, Benin, Spain and Austria. And, based on an investor update issued by the company in December 2009, INVO has started and/or received product registration in 4 additional countries including China, Hong Kong, Taiwan and Thailand, with negotiations pending in 5 more territories---Cyprus, Italy, India, Greece and Russia.
With a presence in more than 30 countries on 5 continents, INVO Bioscience is certainly working towards their goal of providing a more natural, cost-effective infertility treatment geographically available to millions of infertile couples that may otherwise go without treatment.
[edit] Financial Analysis
Revenue figures originally projected by the company in 2009 were created assuming that appropriate funds would be available. INVO Bioscience spent most of 2009 with their attention geared towards acquiring this funding. With the $10,000,000 financing through AGS Capital now in place, the company expects FY2010 revenues between $433,000 - $671,000).
The INVOcell is sold for $125–$400 per unit depending on the market. For instance, in developed countries like Canada the INVOcell is sold for $400 per unit whereas in developing countries the price per unit is significantly less expensive. The cost to manufacture a single INVOcell unit is under $15 which means that gross profit margins will range between 88% - 96%.In order for INVO Bioscience to generate $25 million sales, they would need to attain approximately 57,000 patients out of the 150,000,000 infertile couples worldwide. That’s less than 1/30th of 1% (0.00033333%) of the market. Penetrating 1% of the world market (150 million infertile couples) equates to $660 million in potential revenues.
[edit] Looking Forward
INVO Bioscience plans to start the FDA clearance process this year. In fact, the product development, testing and preclinical work required to support the 510(k) filing is complete and the company has an open IDE (investigational device exemption) to start a clinical study to support the 510(k). Additionally, the company has reported its confidence in this process being completed within the year with FDA clearance in 2011. On October 28, 2009, INVO Bioscience entered into a Reserve Equity Financing Agreement with AGS Capital Group, LLC (“AGS”), pursuant to which AGS committed to purchase, from time to time over a period of two years, shares of IVOB common stock for cash consideration up to $10,000,000.
More recently, the company announced that the National Institutes of Health (NIH) and World Health Organization (WHO) has approved a 100 patient study, which will be conducted by Galaxy IVF in three separate INVO centers in Pakistan, and recruitment for the study is underway. The resulting data from this clinical study will support the widespread acceptance of the INVO procedure in the Middle East and could further validate the efficacy of the company's infertility treatment as comparable to IVF procedures currently in use around the world.
By establishing the INVO procedure as an effective, less expensive and more geographically available treatment, INVO Bioscience has taken more than baby steps towards becoming a leader in the world infertility market.
http://en.wikipedia.org/wiki/INVO_Bioscience
USA Synthetic Fuel Corporation Receives $50 Million Reserve Equity Financing from AGS Capital Group
* Reuters is not responsible for the content in this press release.
Thu May 19, 2011 2:37pm EDT
USA Synthetic Fuel Corporation Receives $50 Million Reserve Equity Financing from AGS Capital Group
USA Synthetic Fuel Corporation (OTCQB:USFC), a leading cleantech company focused on ultra clean btu converter commercial deployment, confirms it has received a $50,000,000 Reserve Equity Financing facility from AGS Capital Group, LLC, a US based specialist investor group, to provide funding for Lima Energy, Cleantech Energy, and corporate growth.
The Reserve Equity Financing is a long-term strategic financing partnership that places USA Synthetic Fuel in control of how and when equity is raised, minimizing any potential dilution or disruption to the company’s capital structure. USA Synthetic Fuel has discretion to periodically sell common shares when the prices are attractive. The Company decides when the funds are raised and how the funds are utilized. Having AGS Capital Group as a long-term partner reduces financing uncertainty so the Company can better focus on achieving its business objectives.
About USA Synthetic Fuel Corporation
USA Synthetic Fuel Corporation (OTCQB:USFC) is an environmental energy technology Company focused on building ultra clean Btu converters designed to enable America’s solid hydrocarbon resources to be transformed into low cost synthetic fuel products: pipeline quality synthetic natural gas (SNG), transportation fuel (diesel, jet, gasoline), hydrogen, and power. USA Synthetic Fuel’s goal is to deliver top environmental, economic, and social performance. The Company’s leading Btu converters are in development and/or construction and are designed to produce 100,000 BOE (barrels of oil equivalent) per day of low cost synthetic fuel. The Company has established the long-term business objective of manufacturing and delivering 2 million BOE/day of low cost synthetic fuel in the USA by 2030. The company owns 1.02 Billion BOE in solid hydrocarbon energy. Additional information may be found at www.usasfc.com
About AGS Capital Group, LLC
AGS Capital Group provides flexible equity financing solutions for growth-stage and mature public companies as well as private companies looking to go public. With offices in New York, Hong Kong and India, AGS Capital Group has facilitated the growth of companies within the U.S. and those domiciled in foreign markets around the globe. AGS Capital Group invests in public companies listed on most exchanges and performs fundamental analysis including credit risk, technical analysis of market trends and industry, evaluation of management team experience and corporate structure evaluation. Additional information may be found at www.agscapitalgroup.com
Forward-Looking Statements
Statements in this news release that are not descriptions of historical facts are forward-looking statements. Reference is made in particular to the descriptions of our plans to, and objectives for, future operations, assumptions underlying such plans and objectives and other forward-looking terminology such as “may”, “expects”, “believes”, “anticipates”, “intends”, “projects”, or similar terms, variations of such terms or the negative of such terms. Forward-looking statements are based on management’s current beliefs, opinions, and expectations. Actual results could differ materially from those currently anticipated due to a number of factors. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including our Form 10.
http://www.reuters.com/article/2011/05/19/idUS210936+19-May-2011+BW20110519
USA Synthetic Fuel Corporation Receives $50 Million Reserve Equity Financing from AGS Capital Group
USA Synthetic Fuel Corporation Receives $50 Million Reserve Equity Financing from AGS Capital Group
USA Synthetic Fuel Corporation (OTCQB:USFC), a leading cleantech company focused on ultra clean btu converter commercial deployment, confirms it has received a $50,000,000 Reserve Equity Financing facility from AGS Capital Group, LLC, a US based specialist investor group, to provide funding for Lima Energy, Cleantech Energy, and corporate growth.
The Reserve Equity Financing is a long-term strategic financing partnership that places USA Synthetic Fuel in control of how and when equity is raised, minimizing any potential dilution or disruption to the company’s capital structure. USA Synthetic Fuel has discretion to periodically sell common shares when the prices are attractive. The Company decides when the funds are raised and how the funds are utilized. Having AGS Capital Group as a long-term partner reduces financing uncertainty so the Company can better focus on achieving its business objectives.
About USA Synthetic Fuel Corporation
USA Synthetic Fuel Corporation (OTCQB:USFC) is an environmental energy technology Company focused on building ultra clean Btu converters designed to enable America’s solid hydrocarbon resources to be transformed into low cost synthetic fuel products: pipeline quality synthetic natural gas (SNG), transportation fuel (diesel, jet, gasoline), hydrogen, and power. USA Synthetic Fuel’s goal is to deliver top environmental, economic, and social performance. The Company’s leading Btu converters are in development and/or construction and are designed to produce 100,000 BOE (barrels of oil equivalent) per day of low cost synthetic fuel. The Company has established the long-term business objective of manufacturing and delivering 2 million BOE/day of low cost synthetic fuel in the USA by 2030. The company owns 1.02 Billion BOE in solid hydrocarbon energy. Additional information may be found at www.usasfc.com
About AGS Capital Group, LLC
AGS Capital Group provides flexible equity financing solutions for growth-stage and mature public companies as well as private companies looking to go public. With offices in New York, Hong Kong and India, AGS Capital Group has facilitated the growth of companies within the U.S. and those domiciled in foreign markets around the globe. AGS Capital Group invests in public companies listed on most exchanges and performs fundamental analysis including credit risk, technical analysis of market trends and industry, evaluation of management team experience and corporate structure evaluation. Additional information may be found at www.agscapitalgroup.com
Forward-Looking Statements
Statements in this news release that are not descriptions of historical facts are forward-looking statements. Reference is made in particular to the descriptions of our plans to, and objectives for, future operations, assumptions underlying such plans and objectives and other forward-looking terminology such as “may”, “expects”, “believes”, “anticipates”, “intends”, “projects”, or similar terms, variations of such terms or the negative of such terms. Forward-looking statements are based on management’s current beliefs, opinions, and expectations. Actual results could differ materially from those currently anticipated due to a number of factors. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including our Form 10.